Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL200644 | 1.00 | MME (0.44) | MMERAB9ALTA4HTSHRNFKB1 | |
| SCHEMBL27524619 | 1.00 | MME (0.44) | MMERAB9ALTA4HTSHRNFKB1 | |
| SCHEMBL203100 | 0.98 | MME (0.43) | MMERAB9ALTA4HTSHRNFKB1 | |
| SCHEMBL6037209 | 0.98 | MME (0.43) | MMERAB9ALTA4HTSHRNFKB1 | |
| SCHEMBL158231 | 0.98 | MME (0.43) | MMERAB9ALTA4HTSHRNFKB1 | |
| SCHEMBL6102241 | 0.96 | MME (0.41) | MMERAB9ALTA4HTSHRNFKB1 | |
| SCHEMBL6102246 | 0.96 | MME (0.41) | MMERAB9ALTA4HTSHRNFKB1 | |
| SCHEMBL5328399 | 0.91 | RAB9A (0.42) | MMERAB9ALTA4HTSHRNFKB1 | |
| SCHEMBL7848861 | 0.91 | MME (0.39) | MMERAB9ALTA4HTSHRNFKB1 | |
| SCHEMBL3418395 | 0.86 | MME (0.36) | MMERAB9ALTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 752 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025064873-A2 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE JOHNS HOPKINS UNIVERSITY (US) | 2025-03-27 | — | — | WO | disclosed |
| EP-4400164-A2 | A METHOD OF INDUCING CARDIOMYOCYTES PROLIFERATION AND TREATING HEART DISEASES | Yeda Research and Development Co. Ltd (IL) | 2024-07-17 | — | — | EP | disclosed |
| US-20240190919-A1 | PEPTIDE COMPOUNDS AND THERAPEUTIC USES OF SAME | IMMUNITY PHARMA LTD. (IL) | 2024-06-13 | — | — | US | disclosed |
| US-20240181020-A1 | TREATMENT OF HYPOPARATHYROIDISM | ENTERA BIO LTD. (IL) | 2024-06-06 | — | — | US | disclosed |
| US-20240182532-A1 | MICROPEPTIDES AND USES THEREOF | FUNDACIÓ PRIVADA INSTITUT D'INVESTIGACIÓ ONCOLÒGICA DE VALL HEBRON (ES) | 2024-06-06 | — | — | US | disclosed |
| US-20240094224-A1 | ANTI-MICROBIAL PEPTIDE (AMP) SIGNATURES FOR DIAGNOSTICS, STRATIFICATION, AND TREATMENT OF MICROBIOME-ASSOCIATED DISEASE | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2024-03-21 | — | — | US | disclosed |
| US-20240076346-A1 | TYPE I MEMBRANE PROTEINS HETERODIMERS AND METHODS OF USE THEREOF | KAHR MEDICAL LTD. (IL) | 2024-03-07 | — | — | US | disclosed |
| US-11912790-B2 | Peptide compounds and therapeutic uses of same | IMMUNITY PHARMA LTD. (IL) | 2024-02-27 | — | — | US | disclosed |
| US-20240042104-A1 | METHOD OF INDUCING CARDIOMYOCYTES PROLIFERATION AND TREATING HEART DISEASES | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2024-02-08 | — | — | US | disclosed |
| US-20240034753-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. | 2024-02-01 | — | — | US | disclosed |
| WO-2001081540-A2 | GROWTH FACTOR WHICH ACTS THROUGH ERB B-4 RTK | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2001-11-01 | — | — | WO | disclosed |
| EP-1080105-A1 | PHENYLALANINE DERIVATIVES HAVING VLA-4 ANTAGONISTIC ACTIVITY | CELLTECH THERAPEUTICS LIMITED (GB) | 2001-03-07 | — | — | EP | disclosed |
| WO-2000001802-A2 | PEPTIDE ANTAGONISTS OF THE HUMAN UROKINASE RECEPTOR AND METHOD FOR SELECTING THEM | CANCERFORSKNINGSFONDEN AF 1989 (FONDEN TIL FREMME AF EKSPERIMENTEL CANCERFORSKNING) (DK) | 2000-01-13 | — | — | WO | disclosed |
| WO-1999061465-A1 | PHENYLALANINE DERIVATIVES HAVING VLA-4 ANTAGONISTIC ACTIVITY | CELLTECH THERAPEUTICS LIMITED (GB) | 1999-12-02 | — | — | WO | disclosed |
| EP-0842281-A1 | PEPTIDE ANALOG INHIBITORS OF UROKINASE RECEPTOR ACTIVITY | CHIRON CORPORATION (US) | 1998-05-20 | — | — | EP | disclosed |
| EP-0672049-A4 | SUPPORT FOR THE SYNTHESIS OF MODULAR POLYMERS. | CHIRON MIMOTOPES PTY LTD (AU) | 1997-10-15 | — | — | EP | disclosed |
| WO-1997005257-A1 | PEPTIDE ANALOG INHIBITORS OF UROKINASE RECEPTOR ACTIVITY | CHIRON CORPORATION (US) | 1997-02-13 | — | — | WO | disclosed |
| EP-0672049-A1 | SUPPORT FOR THE SYNTHESIS OF MODULAR POLYMERS | CHIRON MIMOTOPES PTY. LTD. (AU) | 1995-09-20 | — | — | EP | disclosed |
| WO-1994011388-A1 | SUPPORT FOR THE SYNTHESIS OF MODULAR POLYMERS | CHIRON MIMOTOPES PTY. LTD. (AU) | 1994-05-26 | — | — | WO | disclosed |
| WO-1994003483-A1 | ENDOTHELIN RECEPTOR-BINDING COMPOUNDS | CHIRON CORPORATION (US) | 1994-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240181020-A1 | TREATMENT OF HYPOPARATHYROIDISM | PTH1R, PTMS, CYP24A1 | MME 76/4885RAB9A 3480/4885LTA4H 2566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.